Avalo Therapeutics, Inc.
AVTXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Avalo Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Avalo Therapeutics, Inc. — 10-K filed Mar 23, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 13 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 25, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Avalo Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-05-06 · VARKI PAUL: Larger than 30 of the 33 other insider sales of Common Stock on file. SEC filing
- 2026-05-06 · Doyle Mittie: Larger than 31 of the 33 other insider sales of Common Stock on file. SEC filing
- 2023-06-27 · ARMISTICE CAPITAL, LLC: Larger than 32 of the 33 other insider sales of Common Stock on file. SEC filing
- 2023-06-26 · ARMISTICE CAPITAL, LLC: Larger than all 33 other insider sales of Common Stock on file. SEC filing
- 2023-02-07 · ARMISTICE CAPITAL, LLC: Larger than all 39 other insider purchases of Common Stock on file. SEC filing
- 2022-03-07 · ARMISTICE CAPITAL, LLC: Larger than 38 of the 39 other insider purchases of Common Stock on file. SEC filing
- 2022-03-04 · ARMISTICE CAPITAL, LLC: Larger than 36 of the 39 other insider purchases of Common Stock on file. SEC filing
- 2022-02-17 · ARMISTICE CAPITAL, LLC: Larger than 37 of the 39 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2023-06-09–2023-06-16: 8 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
- 2023-06-08–2023-06-15: 8 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
- 2023-06-07–2023-06-14: 8 event(s) across 3 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-23 | Doyle Mittie · Chief Medical Officer | Common Stock | S — Open market or private sale | −1,450 | 18.00 | SEC filing |
| 2026-05-28 | Doyle Mittie · Chief Medical Officer | Common Stock | S — Open market or private sale | −679 | 16.00 | SEC filing |
| 2026-05-15 | Doyle Mittie · Chief Medical Officer | Common Stock | S — Open market or private sale | −3,000 | 18.76 | SEC filing |
| 2026-05-07 | Sullivan Christopher Ryan · Chief Financial Officer | Common Stock | S — Open market or private sale | −18,606 | 24.12 | SEC filing |
| 2026-05-06 | Sullivan Christopher Ryan · Chief Financial Officer | Common Stock | S — Open market or private sale | −8,900 | 22.57 | SEC filing |
| 2026-05-06 | VARKI PAUL · Chief Legal Officer | Common Stock | S — Open market or private sale | −9,253 | 22.70 | SEC filing |
| 2026-05-06 | Doyle Mittie · Chief Medical Officer | Common Stock | S — Open market or private sale | −10,058 | 22.88 | SEC filing |
| 2026-05-06 | Doyle Mittie · Chief Medical Officer | Common Stock | S — Open market or private sale | −44,944 | 21.20 | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-23 | Doyle Mittie · Chief Medical Officer | Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −1,450 | SEC filing |
| 2026-06-23 | Doyle Mittie · Chief Medical Officer | Common Stock | M — Exercise or conversion of derivative security | +1,450 | SEC filing |
| 2026-06-23 | Philip Ron M · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +40,200 | SEC filing |
| 2026-06-10 | Doyle Mittie · Chief Medical Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −1,084 | SEC filing |
| 2026-06-10 | Riley Jennifer · Chief Strategy Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −588 | SEC filing |
| 2026-06-10 | VARKI PAUL · Chief Legal Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −1,081 | SEC filing |
| 2026-06-10 | Sullivan Christopher Ryan · Chief Financial Officer | Common Stock | F — Payment of exercise price or tax by delivering securities | −138 | SEC filing |
| 2026-06-02 | KAPLAN GILLA · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +20,100 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2023-02-03 | ARMISTICE CAPITAL, LLC · 10% owner | Common Stock | L — Small acquisition | +334 | SEC filing |
Showing 1 of 1 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.